Network pharmacological and molecular docking study of the effect of Liu-Wei-Bu-Qi capsule on lung cancer

doi:10.12998/wjcc.v11.i31.7593

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 31

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4786)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series, Tables (1-5) series.

Item

Count

PDF

183

WORD

HTML

2125

Figures (1-7)

497

Tables (1-5)

438

Sum=3265

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

235

Download

1066

Sum=1301

Nov 6, 2023 (publication date) through Feb 23, 2026

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Clin Cases. Nov 6, 2023; 11(31): 7593-7609
Published online Nov 6, 2023. doi: 10.12998/wjcc.v11.i31.7593

Network pharmacological and molecular docking study of the effect of Liu-Wei-Bu-Qi capsule on lung cancer

Qing Yang, Li-Yuan Li

Qing Yang, Li-Yuan Li, The Second Department of Oncology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, Anhui Province, China

Author contributions: Yang Q and Li LY contributed equally to this work; Yang Q and Li LY designed the study; Yang Q contributed to the analysis of the manuscript; Yang Q and Li LY were involved in the data and writing of this article; and all authors have read and approved the final manuscript.

Institutional review board statement: This study adopts network pharmacology and molecular docking simulation methods without requiring hospital ethical approval.

Informed consent statement: This study did not involve human experiments and does not require the signing of an informed consent form.

Conflict-of-interest statement: Yang Q and Li LY Declaration that there is no conflict of interest.

Data sharing statement: No additional data are available.

STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

Corresponding author: Qing Yang, MMed, Doctor, The Second Department of Oncology, The First Affiliated Hospital of Anhui University of Chinese Medicine, No. 117 Meishan Road, Hefei 230031, Anhui Province, China. cbdcnmyy929@sina.com

Received: August 23, 2023
Peer-review started: August 23, 2023
First decision: September 13, 2023
Revised: October 9, 2023
Accepted: October 23, 2023
Article in press: October 23, 2023
Published online: November 6, 2023
Processing time: 74 Days and 23.9 Hours

ARTICLE HIGHLIGHTS

Research background

Lung cancer (LC) is the second highest disease in the world in terms of incidence rate and the main cause of cancer-related deaths.

Research motivation

Liu-Wei-Bu-Qi capsule (LBC) can reduce radiotherapy and chemotherapy-induced side effects such as anorexia and hair loss, and improve the immune response of tumor patients, and improve the quality of life for patients.

Research objectives

The purpose of this study is to investigate the potential targets and signaling pathways of LBC in the treatment of LC.

Research methods

Network pharmacology and molecular docking simulations were used to analyze the relationship among the main components, targets, and signaling pathways of LBC in treatment of LC.

Research results

The analysis results indicate that the main component for treating LC in LBC may be quercetin, which may be used to treat LC by regulating the endothelial growth factor signaling pathway, Toll like receptor signaling pathway, prolactin signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, and HIF-1 signaling pathway. Molecular docking simulations indicate that quercetin has the best affinity for MAPK3, suggesting that quercetin in LBC may play an important role in the treatment of LC.

Research conclusions

The results showed that the active ingredients in LBC can play a crucial role in the treatment of LC by regulating multiple signaling pathways.

Research perspectives

Predicting potential targets and mechanisms for LBC treatment of LC based on network pharmacology and molecular docking.